This is a routine governance filing with no immediate trading catalyst. The equity plan expansion signals potential future equity grants to retain/attract talent, but does not indicate near-term business changes. Monitor upcoming ASCO data presentations (May 29-June 2) for CRB-701 and CRB-913 pipeline catalysts.
Price Chart
Executive Summary
Corbus Pharmaceuticals appointed Brent Pfeiffenberger to its Board of Directors and shareholders approved an amendment to the 2024 Equity Compensation Plan, increasing authorized shares by 3,000,000 to 5,000,000. The appointment adds a pharma industry veteran with oncology and commercialization expertise, while the equity plan expansion provides additional compensation capacity. The filing is routine governance and compensation matters with no material financial impact.
Key Facts
- Brent Pfeiffenberger appointed to the Board of Directors, expanding the Board to seven members
- Pfeiffenberger is President and CEO of Century Therapeutics (NASDAQ: IPSC) and former SVP at Bristol-Myers Squibb
- Shareholders approved amendment to 2024 Equity Compensation Plan, increasing authorized shares from 2,000,000 to 5,000,000
- All six director nominees were elected with over 95% votes for each
- Advisory vote on executive compensation approved with 9,325,932 votes for (92.6% of votes cast excluding broker non-votes)
- Ratification of EisnerAmper LLP as independent auditor approved with 14,102,264 votes for (99.9% of votes cast)
Financial Impact
Equity plan expansion adds 3,000,000 shares (150% increase from prior 2,000,000) for future compensation grants; no immediate dilution as shares are authorized but not yet issued
Risk Factors
- Equity plan expansion could lead to future dilution if all 3,000,000 additional shares are granted and vested
- No material financial data or guidance provided in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-222890 |
| Document: crbp-ex99_1.htm | 0001193125-26-222890 |
| Document: crbp-ex10_1.htm | 0001193125-26-222890 |
| Document: 0001193125-26-222890-index-headers.html | 0001193125-26-222890 |
| Document: 0001193125-26-222890-index.html | 0001193125-26-222890 |
| Document: 0001193125-26-222890.txt | 0001193125-26-222890 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 8-K | $4.33 | awaiting T+60 | — | $4.07 (−6.00%) |
Sep 30, 2026 26d ago | SC 13G | $6.34 | awaiting T+60 | — | $4.07 (−35.80%) |
Sep 22, 2026 5w ago | Institutional Cluster | $7.88 | awaiting T+60 | — | $4.07 (−48.32%) |
Sep 14, 2026 6w ago | 8-K | $8.08 | awaiting T+60 | — | $4.07 (−49.63%) |
Sep 11, 2026 6w ago | Press Release | $8.08 | awaiting T+60 | — | $4.07 (−49.63%) |
Aug 12, 2026 10w ago | Insider Cluster | $10.08 | awaiting T+60 | — | $4.07 (−59.62%) |
Aug 10, 2026 11w ago | Insider Cluster | $9.51 | awaiting T+60 | — | $4.07 (−57.20%) |
May 26, 2026 22w ago | 8-K | $7.91 $9.99 | ▲ +26.30% | ▲ +23.57% | $4.07 (−48.55%) |
May 21, 2026 22w ago | 8-K | $11.51 $10.49 | ▼ −8.86% | ▼ −13.16% | $4.07 (−64.64%) |
May 14, 2026 23w ago | 8-K | $11.98 $9.46 | ▼ −21.04% | ▼ −24.62% | $4.07 (−66.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers